https://rijournals.com/biological-and-applied-science/

RESEARCH INVENTION JOURNAL OF BIOLOGICAL AND APPLIED SCIENCES 4(2):46-50, 2024

©RIJBAS Publications ISSN: 1597-2879

https://doi.org/10.59298/RIJBAS/2024/424650

Evaluating Continuous Glucose Monitoring as an Intervention for Improving Glycemic Control in Middle-Aged Adults with Type 2 Diabetes

Musimenta Allen

Department of Nursing Kampala International University Uganda
Email: allen.musimenta@studwc.kiu.ac.ug

ABSTRACT

Type 2 diabetes (T2D) presents significant challenges for glycemic control, especially among middle-aged adults who face declining insulin sensitivity and multiple comorbidities. Traditional glucose monitoring methods, such as self-monitoring of blood glucose (SMBG) and hemoglobin A1c (HbA1c) measurements, often fail to capture glucose variability and episodes of hypoglycemia or hyperglycemia. Continuous glucose monitoring (CGM) offers a comprehensive alternative, providing real-time data and enabling proactive management of blood sugar levels. This review examined the clinical efficacy of CGM in improving glycemic control for middle-aged adults with T2D. It highlighted CGM's ability to reduce HbA1c, increase time in range (TIR), and detect nocturnal hypoglycemia, while also discussing its impact on patient behavior, psychological well-being, and adherence to treatment regimens. The methodology for this review involved an in-depth analysis of peer-reviewed studies and clinical trials, focusing on the use of CGM in middle-aged adults with T2D. Barriers to CGM adoption, such as cost and perceived complexity, are also discussed, alongside the potential for future advancements in CGM technology to expand its role in personalized diabetes care. This article underscored the importance of CGM in achieving better long-term glycemic outcomes and improving quality of life for this population.

Keywords: Continuous Glucose Monitoring (CGM), Type 2 Diabetes (T2D), Glycemic Control, Time in Range (TIR), Patient Empowerment.

INTRODUCTION

Type 2 diabetes (T2D) is a prevalent and growing health challenge, particularly among middle-aged adults, a demographic often facing multiple metabolic and lifestyle complications. Effective glycemic control is crucial in managing T2D, as poor management increases the risk of long-term complications such as cardiovascular disease, neuropathy, retinopathy, and nephropathy[1, 2]. (SMBG) and periodic measurement of hemoglobin A1c (HbA1c), offer valuable but limited insights. While these methods provide an overview of average glucose control and immediate blood sugar readings, they miss critical information about glucose variability and fail to capture dangerous episodes of hypoglycemia or hyperglycemia, particularly during the night [3–5]. Continuous glucose monitoring (CGM) has emerged as a transformative technology in diabetes care, providing real-time, comprehensive data on interstitial glucose levels throughout the day. CGM offers significant advantages over traditional methods by tracking glucose trends continuously and enabling timely interventions to prevent extremes in glucose levels. In middle-aged adults with T2D, who often experience declining insulin sensitivity and complex comorbidities, CGM presents a powerful tool to improve daily glucose management and long-term outcomes[6–8]. This review explores the clinical efficacy of CGM as an intervention for improving glycemic control in middle-aged adults with T2D. It examines the physiological mechanisms of CGM, the clinical benefits for this population, and potential barriers to its adoption. Given the increasing burden of T2D in middle age, understanding the role of CGM in improving glycemic outcomes is essential for optimizing treatment strategies and enhancing quality of life.

THE CHALLENGE OF GLYCEMIC CONTROL IN MIDDLE-AGED ADULTS WITH T2D

Middle-aged adults (defined as those between the ages of 45 and 64) represent a particularly vulnerable group in the global T2D epidemic[9]. During this life stage, individuals often experience multiple comorbidities, including hypertension, dyslipidemia, and obesity, all of which compound the difficulty of managing T2D. Insulin sensitivity progressively declines with age, and β-cell function deteriorates, necessitating increasingly complex treatment regimens[10, 11]. As a result, maintaining tight glycemic control becomes more challenging as patients age. Effective management of T2D in this population is essential not only for reducing the risk of acute complications such as hyperglycemia and hypoglycemia but also for preventing long-term sequelae like cardiovascular disease, retinopathy, and nephropathy. Traditional approaches to monitoring glycemic control, such as periodic HbA1c measurements and SMBG, provide important but incomplete data. HbA1c offers a snapshot of average blood glucose levels over the preceding two to three months but does not reflect daily or hourly glucose fluctuations. SMBG, while useful for identifying immediate glucose levels, fails to capture glucose trends between measurements and may miss episodes of hyperglycemia or hypoglycemia that occur during the night or between meals[12–14].

MECHANISMS AND FUNCTIONALITY OF CONTINUOUS GLUCOSE MONITORING

CGM technology offers a more comprehensive picture of glycemic control by continuously measuring glucose levels in the interstitial fluid, the space between cells, which correlates closely with blood glucose levels. CGM systems typically consist of a small sensor inserted just beneath the skin, a transmitter that sends glucose readings to a receiver or smartphone, and software that displays the glucose trends in real time[15]. These systems can provide glucose readings every five minutes, amounting to nearly 300 readings per day. There are two primary types of CGM: real-time CGM (rtCGM) and intermittently scanned CGM (isCGM). RtCGM devices provide continuous data streams and alert users when glucose levels rise too high or fall too low, enabling proactive adjustments to insulin, diet, or activity. IsCGM systems, on the other hand, require users to scan the sensor to obtain glucose readings, offering a more user-driven approach to monitoring. Both types of CGM provide substantial benefits over SMBG by capturing glucose variability and trends that are often missed with intermittent fingerstick tests. One of the key metrics derived from CGM data is time in range (TIR), which refers to the percentage of time that glucose levels fall within a specified target range, typically 70-180 mg/dL[15–17]. TIR has emerged as an important indicator of glycemic control, with studies showing that higher TIR is associated with reduced risks of microvascular and macrovascular complications. Other important metrics include time spent in hypoglycemia (below 70 mg/dL), time in hyperglycemia (above 180 mg/dL), and glucose variability, all of which are critical for managing T2D effectively[18, 19].

CLINICAL EFFICACY OF CGM IN MIDDLE-AGED ADULTS WITH T2D

A growing body of evidence supports the use of CGM for improving glycemic outcomes in adults with T2D, particularly those in middle age. Clinical trials have demonstrated that CGM can lead to significant reductions in HbA1c, increase TIR, and reduce the frequency of hypoglycemic episodes[20]. The benefits of CGM appear to extend beyond those who are on intensive insulin therapy to include individuals using oral hypoglycemic agents or non-insulin injectables, highlighting its broader applicability. One of the key advantages of CGM in middle-aged adults with T2D is its ability to detect nocturnal hypoglycemia, a common but often under-recognized complication in this population. Nocturnal hypoglycemia can lead to dangerous health outcomes, including cardiovascular events, yet it often goes undetected with SMBG due to the infrequency of nighttime testing. CGM systems equipped with low-glucose alerts can notify users of impending hypoglycemia, allowing for timely intervention and reducing the risk of severe episodes. Moreover, CGM has been shown to improve patient adherence to diabetes management plans. The real-time feedback provided by CGM empowers patients to make informed decisions about their diet, physical activity, and medication dosing.[21] For example, users can observe the immediate effects of a meal on their glucose levels and adjust their carbohydrate intake accordingly. Similarly, they can monitor the impact of exercise on glucose levels and take steps to avoid hypoglycemia during or after physical activity. For middle-aged adults who are often balancing work, family responsibilities, and health management, the flexibility provided by CGM can be particularly valuable. CGM reduces the need for frequent fingerstick tests, which are not only uncomfortable but also time-consuming, making it easier for patients to integrate glucose monitoring into their daily routines[22]. This convenience, coupled with the increased data accuracy, may lead to better long-term glycemic control and improved quality of life.

BEHAVIORAL AND PSYCHOLOGICAL IMPACTS OF CGM USE

Beyond its physiological benefits, CGM has been shown to positively influence the behavioral and psychological aspects of diabetes management. One of the key drivers of improved outcomes in CGM users is the ability to visualize glucose trends in real time[23]. This immediate feedback fosters greater engagement in self-management and

encourages users to take a more active role in their care. For middle-aged adults who may have struggled with glycemic control using traditional monitoring methods, CGM can provide a sense of empowerment and control. Studies have also demonstrated that CGM use is associated with reduced diabetes-related distress, a psychological burden that is common among individuals with T2D. The constant flow of glucose data reduces uncertainty and anxiety, allowing users to feel more confident in their ability to manage their condition. This may be particularly beneficial for middle-aged adults, who often face additional stressors related to work, caregiving, and comorbid health conditions. In addition, CGM has the potential to improve patient-provider communication by providing a rich dataset that can be used during clinical visits. Healthcare providers can review CGM data with patients to identify patterns and make more informed decisions about treatment adjustments[24]. This collaborative approach fosters a stronger patient-provider relationship and may lead to more personalized care.

BARRIERS TO CGM ADOPTION IN MIDDLE-AGED ADULTS

Despite the clear benefits of CGM, several barriers may limit its widespread adoption among middle-aged adults with T2D. One of the primary obstacles is the cost of CGM devices and sensors, which may not be covered by insurance, especially for patients who are not on intensive insulin therapy. While prices have decreased in recent years, the financial burden remains a significant consideration for many individuals, particularly those managing multiple chronic conditions. Another barrier is the perception that CGM is too complex or burdensome for daily use. While modern CGM systems have become more user-friendly, with improved sensor insertion techniques and longer sensor wear times, some patients may still be hesitant to adopt the technology. This reluctance may stem from concerns about the discomfort of sensor insertion, the need to carry additional devices, or the perceived difficulty of interpreting CGM data. Healthcare providers also play a role in the adoption of CGM. Some providers may be hesitant to recommend CGM to middle-aged adults with T2D, particularly those who are not using insulin. There may be a perception that CGM is more appropriate for individuals with type 1 diabetes or those with more advanced T2D. However, emerging evidence suggests that CGM can benefit a broad range of individuals with T2D, including those on oral medications or non-insulin injectables. Educating providers about the potential benefits of CGM for middle-aged adults with T2D may help to overcome this barrier.

THE FUTURE OF CGM IN THE MANAGEMENT OF T2D

Looking ahead, the role of CGM in managing T2D is likely to expand as the technology continues to evolve. Advances in sensor accuracy, user interface design, and data integration are making CGM more accessible and effective for a wider range of patients. For example, newer CGM systems feature improved calibration algorithms, longer sensor wear times, and integration with smartphone apps, making them more convenient and user-friendly. In addition, the growing emphasis on personalized medicine in diabetes care suggests that CGM will play an increasingly central role in treatment plans. The data provided by CGM allows for a more individualized approach to glycemic management, where treatment regimens can be tailored to each patient's unique glucose patterns and lifestyle factors. This personalized approach is particularly important for middle-aged adults, who may have different glycemic targets and management priorities than younger or older individuals with T2D. The integration of CGM data with digital health platforms and telemedicine services also holds promise for enhancing diabetes care. Remote monitoring of CGM data could allow healthcare providers to intervene earlier in cases of deteriorating glycemic control, reducing the risk of complications. Furthermore, as the focus of diabetes management shifts toward more holistic measures of glycemic control, such as TIR and glucose variability, CGM is likely to play an increasingly central role in guiding treatment decisions.

CONCLUSION

Continuous glucose monitoring (CGM) represents a transformative intervention for improving glycemic control in middle-aged adults with type 2 diabetes (T2D). Its ability to provide real-time, comprehensive glucose data, detect nocturnal hypoglycemia, and promote more informed diabetes management practices makes it superior to traditional monitoring methods like self-monitoring of blood glucose (SMBG) and hemoglobin A1c (HbA1c). By offering insights into glucose variability, time in range (TIR), and hypoglycemia or hyperglycemia episodes, CGM empowers patients and healthcare providers to make more tailored adjustments to treatment plans. This review highlights the significant clinical benefits of CGM in this population, including enhanced adherence, reduced diabetes-related distress, and improved patient-provider communication. Despite the barriers to widespread adoption such as cost and perceptions of complexity advances in CGM technology, combined with education and support, hold promise for broader usage. As CGM continues to evolve, its integration into personalized diabetes care for middle-aged adults is likely to become a key component in improving both short-term and long-term health outcomes.

REFERENCES

1. Ugwu, O.P.-C., Alum, E.U., Okon, M.B., Aja, P.M., Obeagu, E.I., Onyeneke, E.C.: Ethanol root extract and fractions of Sphenocentrum jollyanum abrogate hyperglycaemia and low body weight in streptozotocin-induced diabetic Wistar albino rats. RPS Pharmacy and Pharmacology Reports. 2, rqad010 (2023). https://doi.org/10.1093/rpsppr/rqad010
2. Alum, E.U., Umoru, G.U., Uti, D.E., Aja, P.M., Ugwu, O.P., Orji, O.U., Nwali, B.U., Ezeani, N.N., Edwin, N., Orinya, F.O.: Hepato-Protective Effect of Ethanol Leaf Extract OF Datura stramonium in ALLOXAN-INDUCED DIABETIC ALBINO RATS. Journal of Chemical Society of Nigeria. 47, (2022). https://doi.org/10.46602/jcsn.v47i5.819
3. Uti, D., Igile, G., Omang, W., Umoru, G., Udeozor, P., Obeten, U., Ogbonna, O., Ibiam, U., Alum, E., Ohunene, R., Mordi, J., Oplekwu, R., Obio, W.: Anti-Diabetic Potentials of Vernonioside E Saponin; A Biochemical Study. 8, 14234–14254 (2022)
4. Yu, T.S., Song, S., Yea, J., Jang, K.-I.: Diabetes Management in Transition: Market Insights and Technological Advancements in CGM and Insulin Delivery. Advanced Sensor Research. 3, 2400048 (2024). https://doi.org/10.1002/adsr.202400048
5. Freckmann, G., Mende, J.: Continuous glucose monitoring: data management and evaluation by patients and health care professionals – current situation and developments. Journal of Laboratory Medicine. 42, 225–233 (2018). https://doi.org/10.1515/labmed-2018-0119
6. Reddy, N., Verma, N., Dungan, K.: Monitoring Technologies- Continuous Glucose Monitoring, Mobile Technology, Biomarkers of Glycemic Control. In: Feingold, K.R., Anawalt, B., Blackman, M.R., Boyce, A., Chrousos, G., Corpas, E., de Herder, W.W., Dhatariya, K., Dungan, K., Hofland, J., Kalra, S., Kaltsas, G., Kapoor, N., Koch, C., Kopp, P., Korbonits, M., Kovacs, C.S., Kuohung, W., Laferrère, B., Levy, M., McGee, E.A., McLachlan, R., New, M., Purnell, J., Sahay, R., Shah, A.S., Singer, F., Sperling, M.A., Stratakis, C.A., Trence, D.L., and Wilson, D.P. (eds.) Endotext. MDText.com, Inc., South Dartmouth (MA) (2000)
7. Alum, E., P.C., U., Obeagu, E., Extension, K.P.: Beyond Pregnancy: Understanding the Long-Term Implications of Gestational Diabetes Mellitus. INOSR Scientific Research. 11, 63–71 (2024). https://doi.org/10.59298/INOSRSR/2024/1.1.16371
8. Cappon, G., Vettoretti, M., Sparacino, G., Facchinetti, A.: Continuous Glucose Monitoring Sensors for Diabetes Management: A Review of Technologies and Applications. Diabetes Metab J. 43, 383 (2019). https://doi.org/10.4093/dmj.2019.0121
9. Hossain, Md.J., Al-Mamun, Md., Islam, Md.R.: Diabetes mellitus, the fastest growing global public health concern: Early detection should be focused. Health Science Reports. 7, e2004 (2024). https://doi.org/10.1002/hsr2.2004
10. Cayetano-Alcaraz, A.A., Tharakan, T., Chen, R., Sofikitis, N., Minhas, S.: The management of erectile dysfunction in men with diabetes mellitus unresponsive to phosphodiesterase type 5 inhibitors. Andrology. 11, 257–269 (2023). https://doi.org/10.1111/andr.13257
11. Alum, E., P.C., U., Obeagu, E., Aja, P., Ugwu, C., Okon, M.: Nutritional Care in Diabetes Mellitus: A Comprehensive Guide. 11, 16–15 (2023). https://doi.org/10.58538/IJIAR/2057
12. Al-Farabi Kazakh National University, Duisenbek, A.A., Ablaikhanova, N.T., Al-Farabi Kazakh National University, Kaldykaraeva, A.T., Al-Farabi Kazakh National University, Yessenbekova, A.Y., Al-Farabi Kazakh National University, Mukhitdin, B., Al-Farabi Kazakh National University, Esymsiitova, Z.B., Al-Farabi Kazakh National University, Kozhamzharova, L.S., Al-Farabi Kazakh National University: Vascular complications in combination with endothelial dysfunction in patients with type 2 diabetes. Bul. Kar.Univ. "BioMedGeo" Ser. 107, 176–184 (2022). https://doi.org/10.31489/2022BMG3/176-184
13. Chang, S.-Y., Chen, Y.-W., Chenier, I., Tran, S.L.M., Zhang, S.-L.: Angiotensin II type II receptor deficiency accelerates the development of nephropathy in type I diabetes via oxidative stress and ACE2. Exp Diabetes Res. 2011, 521076 (2011). https://doi.org/10.1155/2011/521076
14. Cheng, L., Wang, J., Dai, H., Duan, Y., An, Y., Shi, L., Lv, Y., Li, H., Wang, C., Ma, Q., Li, Y., Li, P., Du, H., Zhao, B.: Brown and beige adipose tissue: a novel therapeutic strategy for obesity and type 2 diabetes mellitus. Adipocyte. 10, 48–65. https://doi.org/10.1080/21623945.2020.1870060
15. Mihai, D., Stefan, D., Stegaru, D., Bernea, G., Vacaroiu, I., Papacocea, T., Lupuşoru, M., Nica, A., Stiru, O., Dragos, D., Olaru, O.: Continuous glucose monitoring devices: A brief presentation (Review). Exp Ther Med. 23, 174 (2021). https://doi.org/10.3892/etm.2021.11097

16. Georga, E.I., Fotiadis, D.I., Tigas, S.K.: 7 - Prediction Models of Hypoglycemia. In: Georga, E.I., Fotiadis, D.I., and Tigas, S.K. (eds.) Personalized Predictive Modeling in Type 1 Diabetes. pp. 153–171. Academic Press (2018)
17. Georga, E.I., Fotiadis, D.I., Tigas, S.K.: 9 - Existing and Potential Applications of Glucose Prediction Models. In: Georga, E.I., Fotiadis, D.I., and Tigas, S.K. (eds.) Personalized Predictive Modeling in Type 1 Diabetes. pp. 201–220. Academic Press (2018)
18. Yapanis, M., James, S., Craig, M.E., O'Neal, D., Ekinci, E.I.: Complications of Diabetes and Metrics of Glycemic Management Derived from Continuous Glucose Monitoring. The Journal of Clinical Endocrinology & Metabolism. 107, e2221–e2236 (2022). https://doi.org/10.1210/clinem/dgac034
19. Ravi, R., Balasubramaniam, V., Kuppusamy, G., Ponnusankar, S.: Current concepts and clinical importance of glycemic variability. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 15, 627–636 (2021). https://doi.org/10.1016/j.dsx.2021.03.004
20. Rodbard, D.: Continuous Glucose Monitoring: A Review of Recent Studies Demonstrating Improved Glycemic Outcomes. Diabetes Technology & Therapeutics. 19, S-25-S-37 (2017). https://doi.org/10.1089/dia.2017.0035
21. Zhou, Z., Sun, B., Huang, S., Zhu, C., Bian, M.: Glycemic variability: adverse clinical outcomes and how to improve it? Cardiovascular Diabetology. 19, 102 (2020). https://doi.org/10.1186/s12933-020-01085-6
22. Beck, R., Riddlesworth, T., Ruedy, K., Ahmann, A., Bergenstal, R., Haller, S., Kollman, C., Kruger, D., Mcgill, J., Polonsky, W., Toschi, E., Wolpert, H., Price, D.: Effect of Continuous Glucose Monitoring on Glycemic Control in Adults with Type 1 Diabetes Using Insulin Injections: The DIAMOND Randomized Clinical Trial. JAMA. 317, 371 (2017). https://doi.org/10.1001/jama.2016.19975
23. Klupa, T., Czupryniak, L., Dzida, G., Fichna, P., Jarosz-Chobot, P., Gumprecht, J., Mysliwiec, M., Szadkowska, A., Bomba-Opon, D., Czajkowski, K., Malecki, M.T., Zozulinska-Ziolkiewicz, D.A.: Expanding the Role of Continuous Glucose Monitoring in Modern Diabetes Care Beyond Type 1 Disease. Diabetes Ther. 14, 1241–1266 (2023). https://doi.org/10.1007/s13300-023-01431-3
24. Jarvis, P.R.E., Cardin, J.L., Nisevich-Bede, P.M., McCarter, J.P.: Continuous glucose monitoring in a healthy population: understanding the post-prandial glycemic response in individuals without diabetes mellitus. Metabolism. 146, 155640 (2023). https://doi.org/10.1016/j.metabol.2023.155640

CITE AS: Musimenta Allen. (2024). Evaluating Continuous Glucose Monitoring as an Intervention for Improving Glycemic Control in Middle-Aged Adults with Type 2 Diabetes. RESEARCH INVENTION JOURNAL OF BIOLOGICAL AND APPLIED SCIENCES 4(2):46-50. https://doi.org/10.59298/RIJBAS/2024/424650